Cochlear Stock

Cochlear EBITDA Margin

The EBITDA Margin of Cochlear (COH.AX) as of Aug 3, 2026 is 22.32 %. In the previous year, EBITDA Margin was 22.79 % — a change of -2.10% (lower).

EBITDA Margin

22.32 %

YoY

-2.10%

Last updated:

EBITDA Margin of Cochlear is 2026 22.32 % . EBITDA Margin of Cochlear was 2025 22.79 % . It decreases by -2.10% lower compared to the previous year.
Access this data via the Eulerpool API

Cochlear Stock analysis

What does Cochlear do? Cochlear Ltd is an Australian-based medical technology company founded in 1981 by engineer Professor Graeme Clark. The company specializes in Cochlear implant systems and other hearing devices. Cochlear Ltd offers accessories, services, and rehabilitation training for individuals with hearing impairments. The company's products are available for both children and adults with varying degrees of hearing loss. Cochlear Ltd operates in different sectors, including Cochlear implant systems, hearing aids, and wireless accessories and streaming systems under the brand names Nucleus® and Baha®. Nucleus® systems utilize a fully implantable cochlear implant and external speech processor to convert sound into electrical signals for interpretation by the brain. Baha® systems are bone-anchored hearing devices for individuals with unilateral to moderate hearing impairments. Cochlear Ltd also provides wireless accessories and streaming systems to connect devices like mobile phones, TVs, and music players to the hearing aids and cochlear implants, improving hearing performance and enhancing social lives. The company has a strong global presence, operating in over 100 countries with headquarters in Australia, multiple production facilities, and research centers. Cochlear Ltd has received numerous awards and recognition for its products and services and is committed to researching and developing new therapies and technologies to improve the lives of individuals with hearing impairments. Cochlear is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cochlear stock

EBITDA Margin of Cochlear is 22.32 % in 2026.

EBITDA Margin of Cochlear changed from 22.79 % to 22.32 %, representing a -2.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Cochlear since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Cochlear with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

Margins — Cochlear

All Key Metrics — Cochlear